Mainz Biomed (NASDAQ:MYNZ – Get Free Report)’s share price was up 2.5% during trading on Wednesday . The stock traded as high as $2.09 and last traded at $2.06. Approximately 30,015 shares traded hands during trading, a decline of 52% from the average daily volume of 62,648 shares. The stock had previously closed at $2.01.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on MYNZ shares. HC Wainwright raised their price target on Mainz Biomed from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, September 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $9.00 price target on shares of Mainz Biomed in a research note on Tuesday, September 26th.
Mainz Biomed Stock Performance
Mainz Biomed (NASDAQ:MYNZ – Get Free Report) last issued its quarterly earnings results on Tuesday, August 15th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.14). The business had revenue of $0.25 million during the quarter, compared to analyst estimates of $0.25 million. Sell-side analysts predict that Mainz Biomed will post -1.88 EPS for the current fiscal year.
About Mainz Biomed
Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test.
- Five stocks we like better than Mainz Biomed
- How to Invest in Music Stocks
- First Solar, an affordable, high-quality green investment
- What is the Dow Jones Industrial Average (DJIA)?
- 5 Dow stocks to track during the market correction
- What is the FTSE 100 index?
- Lean on these stocks during GDP expansion
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.